BackBioxytran Overview

Bioxytran Goodwill

Track Bioxytran's goodwill ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Goodwill
$0.00

Peer trimmed avg / median

Loading

Bioxytran Goodwill History

Loading

Bioxytran vs. peers: Goodwill Comparison

Loading

Bioxytran Goodwill Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bioxytran (BIXT) FAQ

The latest goodwill for BIXT is $0 as of June 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Bioxytran's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIXT's goodwill moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bioxytran's operating scale or balance-sheet position.

A goodwill figure of $0 for BIXT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BIXT's goodwill ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bioxytran's goodwill against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.